Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer
· The pre-defined disease control efficacy threshold in part 1 in the colorectal cancer cohort has been met · The colorectal expansion cohort has been opened for recruitment of 14 additional patients · The pre-defined disease control efficacy threshold in ovarian cancer was not met and this cohort will be closed for enrollmentOslo, Norway, 13 October 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announced that the colorectal cancer cohort in part 1 of the ONCOS-102 and durvalumab trial